Pneumologische Onkologie Tumor Treating Fields (TTFields) therapy with standard systemic therapy in metastatic non-small cell lung cancer following progression on or after platinum-based therapy: global randomized, pivotal (phase 3) LUNAR study

Background: TTFields are electric fields that disrupt cancer cell viability. TTFields therapy is approved for glioblastoma and mesothelioma. The randomized, pivotal (phase 3) LUNAR study (NCT02973789) assessed the efficacy and safety of TTFields therapy with investigator's choice of standard systemic therapy (ST; immune checkpoint inhibitor ICI or docetaxel DTX, standard of care at time of study design) for metastatic non-small cell lung cancer (mNSCLC) progressing on/after platinum-based therapy.